NDA 220341 · Alcon Labs INC
Brytly
Apraclonidine Hydrochloride · Ophthalmic
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Oct 16, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
8
4 Phase 3, 2 recruiting
FAERS reports
20
12 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 28, 2026.
Use Relieves redness of the eye due to minor eye irritations
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- BRYTLY · APRACLONIDINE HYDROCHLORIDE EQ 0.125% BASE · SOLUTION/DROPS, OPHTHALMIC · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Apraclonidine" as an intervention, any sponsor and status, largest first.
- An Investigation of FID 123320 for the Reduction of Ocular Redness in Pediatric and Adult PopulationsPivotal-lookingCompleted
Alcon ResearchIndustry
NCT06538662 · 284 participants · Start Oct 7, 2024 · Primary completion Jan 27, 2025
Drug: Apraclonidine Hydrochloride Ophthalmic Solution; Vehicle · For: Ocular Redness; Eye Irritation
Sites: Newport Beach, California; Colorado Springs, Colorado; Louisville, Kentucky · 8 sites in all
- Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in AdultsPivotal-lookingRecruiting
Alcon ResearchIndustry
NCT07531043 · 230 participants (planned) · Start Sep 30, 2026 · Primary completion Feb 2027
Drug: Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free; Vehicle · For: Ocular Hyperemia
Sites: Los Angeles, California; Newport Beach, California; Pittsburg, Kansas · 9 sites in all
- An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in AdultsPivotal-lookingRecruiting
Alcon ResearchIndustry
NCT07578363 · 178 participants (planned) · Start Sep 27, 2026 · Primary completion Nov 2026
Drug: Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free; Vehicle · For: Ocular Hyperemia
Sites: Northbrook, Illinois; Garner, North Carolina; Shelby, North Carolina · 5 sites in all
- A Double-Masked Comparison of FID 123320 Ophthalmic Solution to Vehicle for the Reduction of Ocular RednessPivotal-lookingCompleted
Alcon ResearchIndustry
NCT06444529 · 159 participants · Start Aug 21, 2024 · Primary completion Nov 14, 2024
Drug: Apraclonidine Hydrochloride Ophthalmic Solution; Vehicle · For: Ocular Redness
Sites: Glendale, California; Garner, North Carolina; Cranberry Township, Pennsylvania · 5 sites in all
- Iopidine to Decrease Intraocular Pressure Rise After InjectionsPivotal-lookingNot yet recruiting
Retina Consultants of DelmarvaAcademic, hospital or other
NCT07891910 · 120 participants (planned) · Start Oct 1, 2026 · Primary completion Dec 1, 2026
Drug: Apraclonidine 1.0% ophthalmic solution · For: Macular Degeneration; Diabetic Retinopathy; Retinal Vein Occlusion and 1 more
Sites: Easton, Maryland
- Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser TrabeculoplastyStatus unknown
Walter Reed Army Medical CenterFederal agency
NCT00567411 · 43 participants (planned) · Start Aug 2006
Drug: brimonidine 0.1%; Apraclonidine 0.5% · For: Glaucoma; Ocular Hypertension
Sites: Washington D.C., District of Columbia
- Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia GravisCompleted
American University of Beirut Medical CenterAcademic, hospital or other
NCT05045248 · 10 participants · Start Jun 1, 2020 · Primary completion Apr 15, 2021
Drug: Apraclonidine Hcl 0.5% Oph Soln · For: Myasthenia Gravis; Ocular Myasthenia Gravis
Sites: Beirut, Lebanon
University of Alabama at BirminghamAcademic, hospital or other
NCT05167760 · 0 participants · Start Dec 2025 · Primary completion Nov 2027
Drug: Apraclonidine · For: Synkinesis; Facial Nerve Palsy
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- adrenal insufficiency3
- drug intolerance3
- injection site reaction3
- vaginal infection3
- drug ineffective2
- heart rate increased2
- vision blurred2
- visual impairment2
- abdominal distension1
- abdominal pain upper1
- activities of daily living impaired1
- affective disorder1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2016 | 2 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 2 |
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.
Li T, Lindsley K, Rouse B, et al. · Ophthalmology 2016 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Apraclonidine and LASIK.
Aslanides IM, Tsiklis NS, Pallikaris IG, et al. · Ophthalmology 2005 · Comment, Letter
- Apraclonidine and my pupil.
Cambron M, Maertens H, Crevits L · Clin Auton Res 2011 · Clinical Trial
- Perioperative medications for preventing temporarily increased intraocular pressure after laser trabeculoplasty.
Zhang L, Weizer JS, Musch DC · Cochrane Database Syst Rev 2017 · Meta-Analysis, Research Support, Non-U.S. Gov't
- The effects of apraclonidine on conjunctival oxygen tension.
Serdahl CL, Galustian J, Lewis RA · Arch Ophthalmol 1989 · Clinical Trial, Randomized Controlled Trial
- Daily cost of newer glaucoma agents.
Stewart WC, Hudgins AC, Pruitt CA, et al. · J Ocul Pharmacol Ther 1999 · Clinical Trial, Comparative Study
Sponsor: Alcon Labs INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.